India’s pharma exports surpass $30 billion in FY25, US top market

Top Stories

»	30 lakh join PM Vishwakarma Scheme in 2 years, 4.7 lakh loans worth Rs 41,188 crore approved
»	India-US trade talks resume amid renewed hopes over tariffs
»	Passenger vehicle sales down in Aug as consumers await GST cuts, 2-wheeler sales up: SIAM
»	Nifty, Sensex open flat as investors wait for fresh cues, US Fed meet outcome
»	India’s GDP growth to remain steady at 6.5 pc, another RBI rate cut likely this fiscal

IANS | 19 Apr, 2025

In a significant achievement, the pharmaceutical exports from India crossed $30 billion in the last financial year (FY25), with the US remaining as a key market with more than one-third of the country's pharma exports.

According to official trade data, the pharmaceutical exports reached $30,467.32 million in FY25, more than 9 per cent increase than $27,851.70 million in FY24.

In the month of March, the pharma exports registered more than 30 per cent surge (year-on-year) to $3,681.51 million, from $2,805.71 million in the same month last fiscal, according to data.

The exports to the US (in value terms) increased 14.29 per cent at $8,953.37 million in FY25. Other countries on top of India's pharma exports were the UK, Brazil, France and South Africa last fiscal.

Meanwhile, a report said last month that domestic pharmaceuticals market is expected to grow 8-9 per cent year-on-year in FY26. The report by India Ratings and Research (Ind-Ra) said the growth in the sector will be at 7.5-8.0 per cent year on year for FY25.

This is “against 6.5 per cent year-on-year in FY24 and 9.9 per cent YoY growth in FY23,” said Krishnanath Munde, associate director at India Ratings and Research.

In February, the pharma market delivered revenue of 7.5 per cent year on year. This growth was driven by growth in price (5.2 per cent YoY) and new launches (2.4 per cent YoY), while volume growth continued to remain muted at negative 0.2 per cent YoY, the report said.

The sector reported growth at an average of 7.3 per cent year-to-date (YTD) in FY25. This was led by price growth (5.5 per cent), new launches growth (2.7 per cent), and volume growth.

The pharma sector in the country is witnessing rapid production growth. The Indian pharma sector has grown at 8 per cent CAGR and has also seen a 9 per cent increase in export rates in 2024, according to a report by McKinsey & Company.

The country also emerged as the world’s largest supplier of generic medicines, with a 9 per cent pharma export growth rate, nearly double the global average, the report said.